Actavis PLC’s major acquisition of Forest Laboratories Inc. (NYSE:FRX) provided a boost for other drug makers Tuesday. “When you look across the spec pharma space, we did expect more consolidation,” Morningstar analyst Michael Waterhouse, accord to Investor’s Business Daily. Forest Laboratories, Inc.(NYSE:FRX) stock opened at $92.80in last session, and closed at $91.04, while the day range ofForest Laboratories, Inc.(NYSE:FRX)stock is $90.21 – $93.50. The stock showed a positive weekly performance of31.67%.
Small-cap biotechnology company Prana Biotechnology (ADR) (NASDAQ:PRAN) has gained publicity recently due to its attempts to develop treatments for some of the world’s most common diseases, in particular Alzheimer’s, Parkinson’s and Huntington’s. Prana Biotechnology Limited (ADR)(NASDAQ:PRAN) stock opened at $8.31, in last session and closed at $10.10, by gaining 39.31%. The 52 week range of $2.09 – $13.29. Company’s market capitalization is $361.89M.
Endo Health Solutions Inc. (NASDAQ: ENDP) announced that it has completed its annual goodwill and in-process research and development (IPR&D) impairment analysis for 2013 and plans to record in fiscal 2013, a pre-tax, non-cash asset impairment charge of approximately $495 million, primarily related to goodwill attributable to the company’s acquisition of American Medical Systems. Endo Health Solutions Inc. (NASDAQ:ENDP)stock increased5.83% and finished the last session at $75.82. The EPS of the stock remained-5.58. Company’s market capitalization is $8.67B.
Orexigen Therapeutics, Inc. (NASDAQ:OREX) is a biopharmaceutical company focused on the treatment of obesity. The Company’s lead product candidate is Contrave(R). Based on successful results of the Light Study, an ongoing cardiovascular outcomes trial, Orexigen’s strategy for Contrave is to pursue approvals worldwide and pharmaceutical partnerships for global commercialization. The Company has submitted applications for marketing authorization in the United States and Europe, with potential approvals in 2014.
Orexigen Therapeutics, Inc. (NASDAQ:OREX) stock opened the session at $6.86, and closed the session at $7.49.The 52 week range of theOrexigen Therapeutics, Inc.(NASDAQ:OREX)stock remained $4.59 – $7.84and the day range was $6.81 – $7.51.